Physician
Ancillary Pathways, LLC
Ancillary Pathways, LLC was paid $62K by Medicaid between Jan 2019 and Nov 2024, across 56 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 31% of everything it billed.
33Billing provider infoANCILLARY PATHWAYS, LLC
MIAMI, FL 33174
MIAMI, FL 33174
33aNPI1942796057assigned 07/02/2018
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$62K
24GClaims33,544
24DCodes billed56
24AFirst – last monthJan 2019 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Florida
Rank by total paid#89 of 207
Median peer was paid$39K
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 388 | $0.00 | |
| 2020 | 356 | $2K | |
| 2021 | 890 | $7K | |
| 2022 | 1,999 | $6K | |
| 2023 | 7,921 | $18K | |
| 2024incomplete | 21,990 | $29K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 31% | 1,111 | 699 | $19K |
| 80053 | Comprehensive metabolic panel | 14% | 5,548 | 2,178 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 9.4% | 6,093 | 2,680 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | 5.2% | 977 | 830 | $3K |
| 82947 | 3.7% | 2,025 | 507 | $2K | |
| 82550 | 3.0% | 1,979 | 1,447 | $2K | |
| 88342 | 2.3% | 574 | 333 | $1K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 1,751 | 590 | $1K |
| 84484 | 2.0% | 771 | 556 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 33 | 26 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.7% | 87 | 71 | $1K |
| 80164 | 1.6% | 330 | 199 | $988.11 |
44 more codes
| 83735 | 1.4% | 945 | $863.87 | |
| 82607 | 1.3% | 327 | $837.92 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 164 | $822.55 |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 825 | $804.84 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 280 | $798.15 |
| 87040 | 1.3% | 256 | $788.18 | |
| 84703 | 1.1% | 751 | $703.72 | |
| 86769 | <1% | 196 | $621.88 | |
| 81001 | <1% | 1,557 | $614.62 | |
| 83605 | <1% | 449 | $567.00 | |
| 80061 | Lipid panel | <1% | 368 | $526.61 |
| 80076 | <1% | 357 | $474.28 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 423 | $458.20 |
| 82746 | <1% | 279 | $429.17 | |
| 84100 | <1% | 769 | $410.83 | |
| 87186 | <1% | 147 | $378.13 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 47 | $375.00 |
| 82805 | <1% | 30 | $342.35 | |
| 81003 | <1% | 815 | $287.41 | |
| 85730 | <1% | 297 | $286.56 | |
| 82397 | <1% | 94 | $269.09 | |
| 83690 | <1% | 312 | $232.06 | |
| 87205 | <1% | 342 | $218.73 | |
| 80349 | <1% | 70 | $216.85 | |
| 87070 | <1% | 231 | $213.42 | |
| 85610 | <1% | 355 | $200.51 | |
| 87088 | <1% | 146 | $200.28 | |
| 86850 | <1% | 55 | $170.27 | |
| 81025 | <1% | 207 | $145.76 | |
| 87077 | <1% | 76 | $111.42 | |
| 82150 | <1% | 131 | $104.99 | |
| 83880 | <1% | 67 | $101.92 | |
| 82728 | <1% | 48 | $92.76 | |
| 84439 | <1% | 73 | $66.41 | |
| 87081 | <1% | 94 | $54.10 | |
| 85652 | <1% | 143 | $39.31 | |
| 83540 | <1% | 48 | $31.38 | |
| 82375 | <1% | 13 | $31.33 | |
| 86900 | <1% | 61 | $30.44 | |
| 86901 | <1% | 59 | $20.31 | |
| 86141 | <1% | 21 | $18.18 | |
| 85379 | <1% | 14 | $10.88 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 303 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYAZIJI, HADI (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Nextgen Pathology | Rockledge, FL | $626K |
| Nextgen Pathology | Melbourne, FL | $72K |
| Nextgen Pathology | Palm Bay, FL | $25K |
| Vitro Molecular Laboratories | Miami, FL | $19K |
| Nextgen Pathology | Cocoa Beach, FL | $12K |
| Nextgen Pathology | Viera, FL | $8K |
| Nextgen Pathology | Melbourne, FL | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.